Drug containers and drug delivery devices

A flexible drug container with a collapsible design and integrated squeezer mechanism addresses the need for reliable drug delivery devices, ensuring sterility and precise dosing for drugs ineffective orally, suitable for various injection methods.

JP7579389B2Active Publication Date: 2024-11-07SANOFI SA(FR)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023081205
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-10-19
Filing Date
2023-05-17
Publication Date
2024-11-07
Estimated Expiration
2038-09-26

AI Technical Summary

Technical Problem

There is a need for improved drug containers and delivery devices that are easy to use and reliable for administering drugs that are ineffective or reduced in efficacy upon oral administration, such as proteins, carbohydrates, and vaccines.

Method used

A flexible drug container with a proximal end and distal end, featuring a collapsible design and a membrane-piercing exit port, integrated into a drug delivery device with a squeezer mechanism to ensure sterility and precise drug delivery.

Benefits of technology

The solution provides a user-friendly and reliable drug delivery system that maintains sterility and ensures accurate dosing, suitable for various administration methods, including subcutaneous, intramuscular, and intravenous injections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579389000001
    Figure 0007579389000001
  • Figure 0007579389000002
    Figure 0007579389000002
  • Figure 0007579389000003
    Figure 0007579389000003
Patent Text Reader

Abstract

To provide improved medicament containers that are simple and reliable in use.SOLUTION: The present disclosure relates to a medicament container 24 configured as a flexible bag including a proximal end and a distal end having an outlet port 25, where the flexible bag is configured to increase in length between the proximal end and the distal end when being collapsed.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates generally to a drug container comprising a bag with an outlet, compressible by a compression means. Additionally, the present disclosure relates to a drug delivery device adapted to receive such a drug container. [Background technology]

[0002] Many drugs need to be injected into the body. This applies, for example, to proteins (such as insulin, growth hormone, and interferon), carbohydrates (such as heparin), antibodies, and most vaccines, especially those drugs that are inactivated or have a significantly reduced efficiency when administered orally. Such drugs are primarily injected through drug containers, which are usually glass or plastic syringes or cartridges. Summary of the Invention [Problem to be solved by the invention]

[0003] There is a need for improved medication containers that are simple to use and reliable.

[0004] It is an object of the present disclosure to provide an improved medication container and an improved drug delivery device. [Means for solving the problem]

[0005] That object is achieved by a medicament container according to claim 1 and by a drug delivery device according to claim 12.

[0006] Exemplary embodiments are provided in the dependent claims.

[0007] According to an aspect of the present disclosure, the drug container is configured as a flexible bag including a proximal end and a distal end having an exit port, where the flexible bag is configured to increase in length between the proximal and distal ends when collapsed.

[0008] In an exemplary embodiment, the exit port comprises a membrane adapted to be pierced by a hollow tube, such as, for example, a hollow needle.

[0009] In an exemplary embodiment, the proximal end of the drug container includes a flat section, i.e., a section where two opposing walls of the bag touch each other such that there is no or very little drug between these two opposing walls in this flat section.

[0010] In an exemplary embodiment, the flat section includes one or more holes for securing the proximal end of the container.

[0011] In an exemplary embodiment, at least two holes are provided, each hole having one of at least two different shapes such that a series of shapes of the holes forms an identifier for the container and / or for the medication contained in the container.

[0012] In an exemplary embodiment, the container has a decreasing profile towards the proximal and / or distal ends of the container.

[0013] In an exemplary embodiment, the inside of the drug container has a coating to prevent the drug from extracting or leaching out of the container material.

[0014] In an exemplary embodiment, the container is configured as a bag comprising a flexible material, such as, for example, plastic, aluminum, polyethylene, thermoplastic elastomer (TPE), PVC (polyvinyl chloride), PVC / NBR (PVC nitrile), TPE-MPR (thermoplastic elastomer - melt processable rubber), TPE-vinyl based, TPE (thermoplastic vulcanizate also known as Santoprene®), POP (polyolefin plastomer), Tee (thermoplastic polyester copolymer), etc.

[0015] In an exemplary embodiment, the drug container is formed by impact extrusion or by injection or blow molding.

[0016] In an exemplary embodiment, the flat section is formed by folding over the initially open proximal end or by joining, particularly ultrasonic welding or gluing.

[0017] In an exemplary embodiment, the medication container contains a medication.

[0018] According to an aspect of the present disclosure, a drug delivery device includes a housing adapted to receive the above-mentioned drug container, a squeezer adapted to crush the drug container when driven by a drive mechanism, and a dual-tip injection needle fixed in the housing, where a proximal tip of the needle is away from the membrane in an initial state before the drug container is crushed. Since the length of the container increases when crushed by the squeezer, the proximal tip of the needle pierces the membrane when the container is crushed. Thus, the container remains sterile until it is crushed.

[0019] In an exemplary embodiment, the squeezer includes at least one roller adapted to crush the drug container when moved in a distal direction while the proximal end of the container remains in a fixed position within the housing, such that when the flexible bag is crushed, as the length increases between the proximal and distal ends, the thin film moves towards the proximal tip, causing the proximal tip to pierce the thin film.

[0020] In an exemplary embodiment, the squeezer includes two rollers adapted to crush the drug container between them as they move in a distal direction. Two rollers can provide better volumetric delivery accuracy than a single roller because they will squeeze the entire drug out of the container, even under high pressure. A single roller can leak behind the single roller under pressure, and thus the drug can become trapped behind the roller as it advances in a distal direction.

[0021] In an exemplary embodiment, the housing includes a roller track for guiding the at least one roller during distal movement.

[0022] In an exemplary embodiment, the drug delivery device includes a drug reservoir containing a drug, as described above.

[0023] The drug delivery device may be an automatic injector, and the drive mechanism may be operated by a mechanical or gas spring, or by an electric motor, hi other embodiments, the drug delivery device may be a pen-type device, in which case the drive mechanism would be manually operated.

[0024] The drug delivery devices described herein can be configured to inject a drug or medication into a patient. For example, delivery can be subcutaneous, intramuscular, or intravenous. Such devices can be operated by the patient or by a caregiver, such as a nurse or doctor, and can include various types of safety syringes, pen injectors, or auto-injectors.

[0025] The devices can include cartridge-based systems that require piercing a sealed ampoule prior to use. The volume of drug delivered with these various devices can range from about 0.5 ml to about 2 ml. Yet another device can include a large volume device ("LVD") or patch pump that is configured to adhere to the patient's skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a "large" volume of drug (usually about 2 ml to about 10 ml).

[0026] When combined with a particular drug, the presently described devices can also be customized to operate within the required specifications. For example, the device can be customized to inject the drug within a certain period of time (e.g., about 3 to 20 seconds for an autoinjector, and about 10 to about 60 minutes for an LVD). Other specifications can include low or minimal levels of discomfort, or some conditions related to human factors, shelf life, expiration date, biocompatibility, environmental considerations, etc. Such variations can occur due to a variety of factors, such as, for example, drugs ranging in viscosity from about 3 cP to about 50 cP. Thus, drug delivery devices often include hollow needles ranging in size from about 25 to about 31 gauge. Common sizes are 27 and 29 gauge.

[0027] The delivery device described herein may also include one or more automated features. For example, one or more of needle insertion, medicament injection, and needle retraction may be automated. Energy for one or more automated steps may be provided by one or more energy sources. The energy sources may include, for example, mechanical, pneumatic, chemical, or electrical energy. For example, mechanical energy sources may include springs, levers, elastomers, or other mechanical mechanisms for storing or releasing energy. One or more energy sources may be combined into a single device. The device may further include gears, valves, or other mechanisms for converting energy into movement of one or more components of the device. One or more automated features of the auto-injector may be activated by an activation mechanism. Such an activation mechanism may include one or more of a button, lever, needle sleeve, or other activation components. Activation may be a one-step or multi-step process. That is, a user must activate one or more activation mechanisms to cause an automated function to occur. For example, a user may depress a needle sleeve against their body to cause a medicament to be injected. Other devices require the user to press a button and retract the needle shield to administer the injection, while others require the user to press the device against the skin, and devices with sensors will automatically activate with a small time delay.

[0028] Additionally, such actuation can activate one or more mechanisms. For example, an actuation sequence can activate at least two of needle insertion, drug injection, and needle retraction. Some devices may also require a particular sequence of steps to occur one or more automated functions. Other devices can operate using steps independent of the sequence.

[0029] Some delivery devices are one or more of a safety syringe, a pen-type injector, or an auto-injector. For example, the delivery device may also include a mechanical energy source configured to automatically inject the medication (commonly found in auto-injectors), and a dose-setting mechanism (commonly found in pen-type injectors).

[0030] Further scope of applicability of the present disclosure will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating exemplary embodiments of the present disclosure, are given by way of illustration only, and that various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art from this detailed description.

[0031] The present disclosure will be more fully understood from the detailed description set forth below and the accompanying drawings, which are given by way of illustration only and do not limit the disclosure. [Brief description of the drawings]

[0032] [Figure 1] FIG. 1 is a schematic diagram of a drug delivery device. [Diagram 2] FIG. 2 is a schematic diagram of an exemplary embodiment of a drug delivery device prior to delivery of a drug. [Diagram 3] FIG. 2 is a schematic diagram of a bag. [Figure 4] FIG. 2 is a schematic diagram of an ultrasonic sealer. [Diagram 5] FIG. 2 is a schematic diagram of the drug delivery device after delivering the drug. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] Corresponding parts are marked with the same reference symbols in all figures.

[0034] According to some embodiments of the present disclosure, an exemplary drug delivery device 10 is shown in FIGS. 1A and 1B.

[0035] The aforementioned device 10 is configured to inject a drug or medication into the body of a patient.

[0036] The device 10 typically includes a housing 11 that contains a reservoir (eg, a syringe or container 24) that contains the agent to be injected, and components necessary to facilitate one or more steps of the delivery process.

[0037] The device 10 may also include a cap assembly 12 that may be removably attached to the housing 11, and in particular to the distal or front end D of the device 10. Typically, a user will need to remove the cap assembly or cap 12 from the housing 11 before the device 10 can be operated.

[0038] As shown, the housing 11 can be substantially cylindrical and have a substantially constant diameter along the longitudinal axis X. The housing 11 can have a distal region 20 and a proximal region 21. The term "distal" refers to a location relatively closer to the injection site and the term "proximal" refers to a location relatively farther from the injection site.

[0039] The device 10 can also include a needle sleeve 13 coupled to the housing 11 such that the sleeve 13 can move relative to the housing 11. For example, the sleeve 13 can move in a longitudinal direction parallel to the longitudinal axis X. In particular, movement of the sleeve 13 in a proximal direction allows a tube or needle 17 to extend from a distal region 20 of the housing 11. Insertion of the needle 17 can be accomplished by several mechanisms. For example, the needle 17 can be in a fixed position relative to the housing 11 and can be initially located within the extended needle sleeve 13. Proximal movement of the sleeve 13 by pressing a distal end of the sleeve 13 against the patient's body and by moving the housing 11 in a distal direction can result in the needle 17 being inserted into the distal region 20 of the housing 11. 13. This relative movement exposes the distal end of needle 17. This relative movement allows the distal end of needle 17 to extend into the patient's body. Because needle 17 is manually inserted by the patient's manual movement of housing 11 relative to sleeve 13, this insertion is referred to as "manual" insertion.

[0040] Another form of insertion is "automated", whereby the needle 17 moves relative to the housing 11. Such insertion can be triggered by movement of the sleeve 13 or by another form of activation, such as, for example, a button 22. As shown in Figures 1A and 1B, the button 22 is located at the proximal or rear end P of the housing 11. However, in other embodiments, the button 22 can also be located on the side of the housing 11. In further embodiments, the button 22 is eliminated and replaced with, for example, a sleeve trigger mechanism provided by, for example, pushing the needle sleeve 13 inside the housing when the drug delivery device is placed on the injection side.

[0041] Other manual or automated functions may include drug injection or needle retraction, or both.

[0042] After injection, needle 17 can be retracted into sleeve 13 or housing 11. Retraction can occur when the user removes device 10 from the patient's body and sleeve 13 moves distally.

[0043] This can be done because the needle 17 remains in a fixed position relative to the housing 11. The distal end of the sleeve 13 can be passed over the distal end of the needle 17, such that the needle 17 is sheathed, and then the sleeve 13 can be locked. Such locking can include locking any proximal movement of the sleeve 13 relative to the housing 11.

[0044] Another form of needle retraction can occur when the needle 17 moves relative to the housing 11. Such movement can occur when the syringe within the housing 11 moves proximally relative to the housing 11. This proximal movement can be accomplished by using a retraction spring (not shown) located in the distal region 20. The compressed retraction spring, when activated, can provide sufficient force against the container 24 to move it proximally. After sufficient retraction, any relative movement between the needle 17 and the housing 11 can be locked using a locking mechanism. Additionally, the button 22, or other components of the device 10, can be locked as desired.

[0045] In some embodiments, the housing can include a window 11a through which the container 24 can be monitored.

[0046] 2 is a schematic diagram of an exemplary embodiment of a drug delivery device 10 before delivery of a drug. The drug delivery device 10 comprises a container 24 filled with a drug, the container 24 being configured as a flexible bag having an exit port 25. The container 24, which preferably has a relatively thin skin, can be compressed by a squeezer 26 comprising a pair of rollers 26.1, 26.2 movable parallel to a longitudinal axis X by a drive mechanism 27. When the rollers 26.1, 26.2 move in a distal direction D along the longitudinal axis X, the proximal end of the container 24 remains in a fixed position within the housing 11, but the container 24 is disposed between the rollers 26.1, 26.2 so as to be crushed. As the rollers 26.1, 26.2 crush the container 24, the volume of the container 24 gradually decreases, so that the drug is squeezed out from the exit port 25. In the exemplary embodiment, the housing 11 comprises a roller track 28 adapted to guide the rollers 26.1, 26.2 and to maintain the distance between the two rollers 26.1, 26.2 as they move forward.

[0047] The rollers 26.1, 26.2 can be spaced apart to take into account the wall thickness of the container 24 so that when the container 24 is completely collapsed and the rollers 26.1, 26.2 are moved, no medicament is trapped thereafter.

[0048] The container 24 can be configured as a plastic blow molded bag or as an aluminum bag. The outlet port 25 is located at the distal end of the container 24, for example by molding. The outlet port 25 can include a thin-walled membrane 31 adapted to be pierced by the proximal tip 17.1 of the double-tipped injection needle 17 fixed in the housing 11. The distal tip 17.2 of the needle 17 can be positioned to extend distally from the housing 11 after removing the cap assembly (not shown) or after depressing the sleeve 13. In the initial state before injection, the proximal tip 17.1 of the needle 17 is away from the membrane 31 of the outlet port 25 so that the contents of the container 24 are sterile and the integrity of the container is maintained. The proximal end of the container 24 includes a flat section 29 (see FIG. 3 ) adapted to be fixed in the housing 11. As the rollers 26.1, 26.2 move in the distal direction D, the flat section 29 remains in a fixed position within the housing 11 held by one or more holes 30, while the container 24 gradually collapses, thus increasing in length, and the outlet port 25 moves towards the proximal tip 17.1 of the needle 17 which then pierces the membrane 31, thus establishing fluid communication between the container 24 and the needle 17.

[0049] In an exemplary embodiment, the container 24 formed as a bag can have a circular, oval, or rectangular contour, in an exemplary embodiment, the contour is not uniform but decreases toward the proximal and distal ends of the container 24, or at least toward the distal or proximal ends.

[0050] In the case of an aluminum bag, the bag can be formed by impact extrusion, where the bag is extruded from a small section of aluminum. The flat section 29 can be formed by folding the initially open proximal end several times, similar to a tube of toothpaste. The bag is thus hermetically sealed and is nearly sterile due to the high temperatures during the bag production process. The inside of the bag can have a coating to prevent the bag material from reacting with the contents.

[0051] In the case of a plastic bag, the flat section 29 may be formed by bonding, for example by applying an adhesive or by welding. The flat section 29 is shown in FIG.

[0052] In the case of a plastic bag, the exit port 25 can be formed by injection molding of a preform to form a membrane 31. The preform can be formed as a miniature version of the bag, for example, including a neck with the final shape and size of the exit port 25, possibly with threads and a small, thick-walled section to form the body portion of the bag that is then blown into the final shape. The preform can be fed into a molding machine, heated and pressurized in a blow molding tool. Compressed air can be used to shape it into the shape of the blow molding tool that forms the final shape. When the preform is made, the neck and threads are injection molded, allowing for a good seal with a very precisely manufactured, injection molded cap, also called a closure. Therefore, no insert or lining is needed inside the closure to create a good leak-proof seal.

[0053] The flat section 29 is a flat section that can be used to secure the container 24 within the housing 11. The housing 11 or drive mechanism 27 may include one or more holes 30. The housing 11 or drive mechanism 27 may have a pin adapted to engage within the hole 30. The holes 30 may have a variety of shapes, such as, for example, a star or asterisk, a square, a circle, a diamond, a triangle, etc. A series of holes 30, each having one of these shapes, may be used to form a unique identifier for the container 24 and / or for the medication contained in the container 24. With three holes 30, using two different symbols, there may be eight different identifiers. With three different symbols, there would be 27 different identifiers, with four different symbols, there would be 64 different identifiers, etc.

[0054] The container 24 may be made of or include a plastic material, such as, for example, polyethylene.

[0055] 4 is a schematic diagram of an ultrasonic sealer 40 including a container holder 41 for receiving a container 24 with the outlet port 25 facing down. The container 24 is filled with drug, for example, from the bottom up. An ultrasonic horn 42 and fitting 43 are placed on the proximal end of the container 24 to close and seal the proximal end by ultrasonic welding to form a flat section 29. In other embodiments, the proximal end of the container 24 can also be sealed by heat or otherwise. Sealing can be performed in a clean room.

[0056] 5 is a schematic diagram of the drug delivery device 10 after drug delivery. The drive mechanism 27 advances the rollers 26.1, 26.2 in a distal direction D, where the flat section 29 remains in place while the container 24 gradually collapses, thus increasing in length, and the outlet port 25 moves towards the proximal tip 17.1 of the needle 17, which pierces the membrane 31 to establish fluid communication between the container 24 and the needle 17. As the rollers 26.1, 26.2 collapse the container 24, the volume of the container 24 is gradually reduced, and finally the drug is squeezed out of the outlet port 25 through the needle 17. After drug delivery, the cap assembly can be returned to the housing 11 to cover the distal end 17.2 of the needle 17.

[0057] The drug delivery device 10 can be an automatic injector and the drive mechanism can be operated by a mechanical or gas spring, or by an electric motor, hi other embodiments, the drug delivery device 10 can be a pen-type device and the drive mechanism is to be manually operated.

[0058] In another exemplary embodiment, instead of rollers 26.1, 26.2, the squeezer 26 may be arranged as a shaft that engages the proximal end of the container 24 and winds it up as the shaft rotates.

[0059] In yet another embodiment, the squeezer 26 may comprise only one roller 26.1 acting against a rigid support on which the container 24 rests.

[0060] In another exemplary embodiment, instead of a double-tipped needle, there may be a needle connected to a tube, the other end of which is connected to another needle or a cannula.

[0061] In an exemplary embodiment, the membrane 31 may be a septum, such as, for example, a pizza-shaped septum, that is applied to reseal the container 24 .

[0062] As used herein, the term "drug" or "medicine" is used herein to describe one or more pharmacologic active compounds. As described below, a drug or medicament can include at least one small molecule or macromolecule, or a combination thereof, of various types of formulations for treating one or more diseases. Exemplary pharma- ceutical active compounds can include small molecules; polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids can be incorporated into vectors, plasmids, or molecular delivery systems such as liposomes. Mixtures of one or more of these drugs are also contemplated.

[0063] The term "drug delivery device" encompasses any type of device or system configured to administer a drug to the human or animal body. Without limitation, the drug delivery device can be an injection device (e.g., a syringe, pen injector, auto-injector, large volume device, pump, perfusion system, or other device configured for intraocular, subcutaneous, intramuscular, or intravascular delivery), a skin patch (e.g., osmotic, chemical, microneedle), an inhaler (e.g., nasal or pulmonary), an implant (e.g., coated stent, capsule), or a delivery system for the gastrointestinal tract. The drugs described herein can be particularly useful in injection devices that include a needle, e.g., a small gauge needle.

[0064] The drug or agent can be contained within a primary package or "drug container" adapted for use in a drug delivery device. The drug container can be, for example, a cartridge, syringe, reservoir, or other container configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more pharma- ceutical active compounds. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber can be designed to store the drug for about one month to about two years. Storage can be at room temperature (e.g., about 20°C) or at refrigerated temperatures (e.g., from about -4°C to about 4°C). In some cases, the drug container can be or include a dual-chamber cartridge configured to store two or more components of a drug formulation (e.g., a drug and a diluent, or two different types of drugs) separately, one in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between the two or more components of the drug or agent before and / or during administration into the human or animal body. For example, the two chambers can be configured such that they are in fluid communication with one another (e.g., by a conduit between the two chambers) to allow for mixing of the two components by a user prior to administration, if desired. Alternatively, or in addition, the two chambers can be configured to allow for mixing of the components as they are being administered into the human or animal body.

[0065] The drug delivery device and drugs described herein can be used to treat and / or prevent many different types of disorders.Exemplary disorders include, but are not limited to, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolism, such as deep vein thromboembolism or pulmonary thromboembolism.Further exemplary disorders are acute coronary syndrome (ACS), angina pectoris, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis.

[0066] Exemplary drugs for the treatment and / or prevention of diabetes or complications associated with diabetes are insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, or an analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma- ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the term "derivative" refers to any substance that is sufficiently structurally similar to the original substance so that it can have a similar function or activity (e.g., therapeutic efficacy).

[0067] Exemplary insulin analogs are Gly(A21),Arg(B31),Arg(B32) human insulin (insulin glargine); Lys(B3),Glu(B29) human insulin; Lys(B28),Pro(B29) human insulin; Asp(B28) human insulin; human insulin in which the proline at position B28 is replaced by Asp, Lys, Leu, Val, or Ala, and in position B29, Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0068] Exemplary insulin derivatives include, for example, B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29Ly sB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin, and B29-N-(ω-carboxyheptadecanoyl) human insulin.Exemplary GLP-1, GLP-1 analogs and GLP-1 receptor agonists include, for example: Lixisenatide / AVE0010 / ZP10 / Lyxumia, Exenatide / Exendin-4 / Byetta / Bydureon / ITCA650 / AC-2993 (a 39 amino acid peptide produced by the salivary glands of the Gila monster), Liraglutide / Victoza, Semaglutide, Taspoglutide, Syncria / Albiglutide, Dulaglutide, glutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C, CM-3, GLP-1 Erigen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX -096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten.

[0069] An exemplary oligonucleotide is, for example: mipomersen / Kynamro, a cholesterol-lowering antisense therapeutic for the treatment of familial hypercholesterolemia.

[0070] Exemplary DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.

[0071] Exemplary hormones include pituitary or hypothalamic hormones or regulatory active peptides and their antagonists, such as gonadotropins (follitropin, lutropin, chorion gonadotropins, menotropins), somatropins (somatropins), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin, and goserelin.

[0072] Exemplary polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin, or very low molecular weight heparin, or derivatives thereof, or sulfated forms of the above polysaccharides, such as polysulfated forms, and / or pharmaceutically acceptable salts thereof. An example of a pharmaceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is HylanG-F20 / Synvisc, sodium hyaluronate.

[0073] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments that retain the ability to bind antigen. The antibody can be polyclonal, monoclonal, recombinant, chimeric, non-immunoglobulin or humanized, fully human, non-human (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix complement. In some embodiments, the antibody has reduced ability to bind or cannot bind Fc receptors. For example, the antibody can be an isotype or subtype, an antibody fragment, or a variant that does not support binding to Fc receptors, e.g., it has a mutated or deleted Fc receptor binding region.

[0074] The term "fragment" or "antibody fragment" refers to a polypeptide derived from an antibody polypeptide molecule (e.g., antibody heavy and / or light chain polypeptides) that does not include the full-length antibody polypeptide, but still includes at least a portion of the full-length antibody polypeptide that can bind to an antigen. An antibody fragment can include a truncated portion of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments that are useful in the present disclosure include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), minibodies, chelating recombinant antibodies, tri- or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies, and VHH-containing antibodies. Further examples of antigen-binding antibody fragments are known in the art.

[0075] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences in the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences in the variable regions of both heavy and light chain polypeptides that are not CDR sequences, but are primarily responsible for maintaining the correct positioning of CDR sequences to allow antigen binding. Although framework regions themselves are usually not directly involved in antigen binding, as is known in the art, certain residues in the framework regions of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDRs to interact with the antigen.

[0076] Exemplary antibodies are anti-PCSK-9 mAb (e.g., Alirocumab), anti-IL-6 mAb (e.g., Sarilumab), and anti-IL-4 mAb (e.g., Dupilumab).

[0077] The compounds described herein can be used in pharmaceutical preparations that include (a) the compound or its pharmaceutically acceptable salt, and (b) a pharmaceutically acceptable carrier.The compounds can also be used in pharmaceutical preparations that include one or more other active pharmaceutical ingredients, or in pharmaceutical preparations in which the compound or its pharmaceutically acceptable salt is the only active ingredient present.Thus, the pharmaceutical preparations of the present disclosure encompass any preparation that is made by mixing the compounds described herein and a pharmaceutically acceptable carrier.

[0078] Pharmaceutically acceptable salts of any of the drugs described herein are also contemplated for use in the drug delivery device. Pharmaceutically acceptable salts are, for example, acid addition salts and base salts. Acid addition salts are, for example, HCl or HBr salts. Base salts are, for example, salts with a cation selected from an alkali or alkaline earth metal, for example Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), where R1 to R4 are each independently: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharma-ceutically acceptable salts are known to those skilled in the art.

[0079] Pharmaceutically acceptable solvates are, for example, hydrates or alkanolates, such as methanolates or ethanolates.

[0080] Those skilled in the art will understand that modifications (addition and / or removal) of the various components of the substances, formulations, devices, methods, systems, and embodiments described herein may be made without departing from the full scope and spirit of the present disclosure, which encompasses such modifications and any and all equivalent forms thereof. [Explanation of symbols]

[0081] 10 Drug Delivery Devices 11. Housing 11a Window section 12 Cap assembly 13 Sleeve 17 needles 17.1 Proximal tip 17.2 Distal Tip 20 Distal Region 21 Proximal Region 22 Buttons 24 Container 25 Exit Port 26 Squeezer 26.1 Lola 26.2 Lola 27 Drive mechanism 28 Rolla Track 29 Flat Section 30 holes 31 Thin Film 40 Ultrasonic sealer 41 Container holder 42 Ultrasonic Horn 43 Mounting fixture D distal end, distal direction P proximal end, proximal direction X Longitudinal Axis

Claims

1. A drug delivery device (10), A housing (11); a drug container (24) containing a drug; A double-tipped injection needle (17) fixed within the housing (11); A drug delivery device (10) comprising: The drug container (24) comprises: A proximal end; A distal end. an exit port disposed at a distal end; a flat section (29) adapted to be fixed within the housing (11), the flat section including one or more holes (30), the flat section (29) being disposed at a proximal end; two opposing sides of an ellipse, each extending along a longitudinal axis (X) of the container (24) from the outlet port (25) to the flat section (29), the profile of the side of the container (24) decreasing continuously along the longitudinal axis (X) towards the flat section (29) and towards the outlet port (25) of the container; The flexible bag includes: The exit port (25) includes a membrane (31) adapted to be pierced by the needle (17); said flexible bag being configured such that, when collapsed, it increases in length between the flattened section (29) and the outlet port (25) such that the outlet port (25) moves towards the proximal tip (17.1) of the needle (17) which then pierces the membrane (31) thereby establishing fluid communication between the container (24) and the needle (17); The drug delivery device (10), wherein the flat section (29) is connected to the housing (11) such that when the flexible bag is crushed, the length increases between the proximal and distal ends such that the flat section (29) is prevented from moving relative to the housing (11) before, during and after the membrane (31) moves toward the proximal tip (17.1).

2. 2. The drug delivery device (10) of claim 1, wherein at least two holes (30) are provided, each hole (30) having one from at least two different shapes, such that a series of shapes forms the identifier.

3. 3. The drug delivery device (10) of claim 1 or 2, wherein the inside of the drug reservoir (24) has a coating to prevent the material of the reservoir (24) from reacting with the drug.

4. The drug delivery device (10) of any one of claims 1 to 3, wherein the container (24) is configured as a bag comprising a flexible material selected from the group consisting of plastic, aluminum, polyethylene, thermoplastic elastomer, polyvinyl chloride, polyvinyl chloride nitrile, thermoplastic elastomer-vinyl based, thermoplastic vulcanizates, polyolefin plastomers and thermoplastic polyester copolymers.

5. The drug delivery device (10) of any one of claims 1 to 4, further comprising a squeezer (26) adapted to crush the drug container (24) when driven by a drive mechanism (27), wherein in an initial state before the drug container (24) is crushed, the proximal tip (17.1) of the needle (17) is separated from the membrane (31).

6. 6. The drug delivery device (10) of claim 5, wherein the squeezer (26) comprises at least one roller (26.1, 26.2) adapted to crush the drug container (24) when moved in a distal direction (D) along the longitudinal axis (X), while the proximal end of the container (24) remains in a fixed position within the housing (11), such that as the flexible bag, when crushed, increases in length between the proximal and distal ends, the membrane (31) moves towards the proximal tip (17.1) such that the proximal tip (17.1) perforates the membrane (31).

7. The drug delivery device (10) of claim 6, wherein the squeezer (26) comprises two rollers (26.1, 26.2) adapted to crush the drug container (24) between them when moved in the distal direction (D), and the housing (11) comprises a roller track (28) for guiding at least one roller (26.1, 26.2) while moving in the distal direction (D).

Citation Information

Patent Citations

  • Beneficial drug dispenser

    JP2013543759A

  • Hypodermic drug delivery reservoir and apparatus

    US20100179473A1